Global Pharma Healthcare Recalls Artificial Tears for Possible Drug-Resistant Bacterial Contamination
On February 1, 2023, the CDC issued a health advisory concerning over-the-counter artificial tear and eye lubricant products distributed by Aru Pharma, EzriCare and Delsam Pharma under Global Pharma Healthcare. The CDC and FDA recommend patients and providers who use the artificial tear products EzriCare and Delsam Pharma stop using them immediately due to possible contamination with pseudomonas aeruginosa bacteria. According to the CDC, the drug-resistant bacteria spreads easily, particularly in healthcare environments. The bacteria can cause severe infections throughout the body, including the blood, lungs, stomach and urinary tract. Infections can be especially devastating to those who are immunocompromised.
From May 2022 to January 2023, the CDC received reports from state and local health departments in California, Colorado, Connecticut, Florida, New Jersey, New Mexico, New York, Nevada, Texas, Utah, Washington and Wisconsin concerning adverse reactions to EzriCare artificial tears. Fifty-five cases individuals who used EzriCare artificial tears reported eye infections, blurred vision, loss of vision and other issues. One individual died when the bacteria entered and infected their bloodstream.
On February 2, 2023, Global Pharma Healthcare issued a voluntary recall of EzriCare and Delsam Pharma artificial tears.
If you or a loved one suffered due to these artificial tears, or if a loved one who used these artificial tears has passed away from a pseudomonas aeruginosa-related bacterial infection, please contact PCVA by filing out the form below.